atropine has been researched along with astressin-2b in 1 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (astressin-2b) | Trials (astressin-2b) | Recent Studies (post-2010) (astressin-2b) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 41 | 0 | 30 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, L; Yin, D; Yin, Y | 1 |
1 other study(ies) available for atropine and astressin-2b
| Article | Year |
|---|---|
Peripheral and central administration of exogenous urocortin 1 disrupts the fasted motility pattern of the small intestine in rats via the corticotrophin releasing factor receptor 2 and a cholinergic mechanism.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atropine; Duodenum; Enzyme Inhibitors; Fasting; Gastrointestinal Motility; Gastrointestinal Transit; Injections, Intravenous; Injections, Intraventricular; Jejunum; Male; Muscarinic Antagonists; Myenteric Plexus; Myoelectric Complex, Migrating; Nitric Oxide Synthase; Nitroarginine; Peptide Fragments; Peptides, Cyclic; Phentolamine; Postprandial Period; Propranolol; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Urocortins | 2008 |